Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Amyris Scales Back Farnesene Plans

by Alexander H. Tullo
February 20, 2012 | A version of this story appeared in Volume 90, Issue 8

Amyris, an Emeryville, Calif.-based start-up that is developing farnesene as a building-block chemical, is pulling back on aggressive expansion plans in light of manufacturing difficulties. The company began production last year at sites run by contract manufacturers in the U.S., Spain, and Brazil. Amyris CEO John G. Melo told analysts in a Feb. 9 conference call that the Brazilian facility has “operational issues.” He said the company has learned that “it takes time to translate from the peak yield levels in the lab to maintaining those yields over longer operational periods in the field.” Amyris will not meet its stated goal of making 40 million to 50 million L of farnesene in 2012, he acknowledged. Additionally, Melo is no longer forecasting that the company will have positive cash flow in 2012. Amyris thus aims to raise money in a round of equity financing, although Melo declined to offer details. Amyris shares plunged 28% the day after his disclosure.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.